\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ patient\\ was\\ referred\\ to\\ pulmonary\\ medicine\\ and\\ eventually\\ to\\ interventional\\ radiology\\ to\\ discuss\\ emobolization\\.\\ feeding\\ vessel\\ diameter\\ measured\\ 3\\ mm\\ and\\ total\\ lesions\\ size\\ was\\ 1\\ cm\\.\\ shunt\\ fraction\\ determined\\ to\\ be\\ 8\\%\\.\\ patient\\ was\\ offered\\ embolization\\ but\\ opted\\ for\\ follow\\ up\\ in\\ 6\\ months\\.\ \(0\)\
\-\ chest\\ x\\-ray\\:\ \(2\)\
\-\ solitary\\ left\\ pulmonary\\ nodule\\.\ \(0\)\
\-\ noncontrast\\ ct\\:\ \(0\)\
\-\ well\\ defined\\,\\ lobular\\ left\\ pulmonary\\ nodule\\ with\\ apparent\\ feeding\\ \\/\\ draining\\ vessel\\.\ \(0\)\
\-\ contrast\\ enhanced\\ ct\\:\\ \ \(0\)\
\-\ prompt\\ pulmonary\\ arterial\\ phase\\ enhancement\\ of\\ well\\ defined\\,\\ lobular\\ left\\ pulmonary\\ nodule\\ with\\ enhancing\\ feeding\\ and\\ draining\\ vessels\\.\ \(0\)\
\-\ pulmonary\\ arteriovenous\\ malformation\ \(5\)\
\-\ pulmonary\\ arteriovenous\\ malformation\ \(5\)\
\-\ cough\\.\ \(59\)\
\-\ pulmonary\\ arteriovenous\\ malformations\\ are\\ abnormal\\ direct\\ connections\\ between\\ the\\ pulmonary\\ arterial\\ and\\ venous\\ systems\\ forming\\ a\\ right\\ to\\ left\\ shunt\\.\\ lesions\\ may\\ be\\ single\\ or\\ multiple\\ and\\ are\\ frequently\\ discovered\\ as\\ solitary\\ pulmonary\\ nodules\\ on\\ chest\\ x\\-ray\\.\\ many\\ are\\ associated\\ with\\ rendu\\-osler\\-weber\\ syndrome\\ and\\ autosomal\\ dominant\\ disorder\\.\\ most\\ often\\ lesions\\ are\\ asymptomatic\\ but\\ they\\ may\\ present\\ with\\ symptoms\\ related\\ to\\ arteriovenous\\ shunting\\.\\ symptoms\\ may\\ include\\ hypoxia\\,\\ dyspnea\\,\\ hemoptysis\\,\\ and\\ possibly\\ from\\ embolic\\ events\\.\\ \ \(0\)\
\-\ on\\ chest\\ x\\-ray\\ finding\\ is\\ usually\\ a\\ pulmonary\\ nodule\\,\\ possibly\\ with\\ a\\ visible\\ feeding\\ vessel\\ extending\\ from\\ the\\ hilum\\.\\ on\\ ct\\,\\ lesions\\ appear\\ somewhat\\ lobulated\\ and\\ well\\ defined\\,\\ also\\ with\\ feeding\\ and\\ draining\\ vessels\\ emanating\\ from\\ and\\ to\\ the\\ hilum\\.\\ the\\ vascular\\ nature\\ of\\ these\\ lesions\\ is\\ well\\ defined\\ with\\ characteristic\\ intravenous\\ contrast\\ enhancement\\.\\ similar\\ findings\\ can\\ also\\ be\\ seen\\ on\\ pulmonary\\ angiography\\.\\ \ \(0\)\
\-\ important\\ radiographic\\ criteria\\ include\\ feeding\\ vessel\\ thickness\\,\\ overall\\ size\\,\\ and\\ shunt\\ fraction\\.\\ lesions\\ are\\ typically\\ recommended\\ for\\ treatment\\ with\\ the\\ feeding\\ vessel\\ is\\ \\>\\ 3\\ mm\\,\\ the\\ lesion\\ is\\ \\>\\ 2\\ cm\\ in\\ size\\,\\ or\\ the\\ shunt\\ fraction\\ is\\ \\>\\ 12\\-15\\ \\%\\.\\ treatment\\ may\\ be\\ surgical\\ or\\ endovascular\\.\\ \ \(0\)\
\-\ treatment\\ is\\ intended\\ to\\ reduce\\ right\\ to\\ left\\ shunting\\ and\\ subsequently\\ to\\ reduce\\ the\\ risk\\ of\\ venous\\ to\\ arterial\\ embolization\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ armstrong\\ p\\.\\ et\\ al\\.\\ imaging\\ of\\ diseases\\ of\\ the\\ chest\\.\\ 3rd\\ edition\\.\\ mosby\\ 2000\\:708\\-711\ \(0\)\
\-\ 2\\.\\ http\\:\\/\\/www\\.amersham\\-health\\.com\\/\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pulmonary\\:\\ 0\\.3656151518622167\ \(0\)\
\-\ feeding\\:\\ 0\\.3281416795591967\ \(0\)\
\-\ vessel\\:\\ 0\\.2192156468237436\ \(0\)\
\-\ arteriovenous\\:\\ 0\\.19178924184954446\ \(0\)\
\-\ shunt\\:\\ 0\\.1895841065238346\ \(0\)\
\-\ fraction\\:\\ 0\\.17799692181694918\ \(0\)\
\-\ lesions\\:\\ 0\\.172240400445234\ \(0\)\
\-\ nodule\\:\\ 0\\.15781166379784975\ \(0\)\
\-\ draining\\:\\ 0\\.1452442675084743\ \(0\)\
\-\ defined\\:\\ 0\\.14263507199504852\ \(0\)\
\-\ to\\:\\ 0\\.13745662080487528\ \(0\)\
\-\ and\\:\\ 0\\.12394451340953849\ \(0\)\
\-\ arterial\\:\\ 0\\.12349040104810954\ \(0\)\
\-\ shunting\\:\\ 0\\.11241386986695537\ \(0\)\
\-\ hilum\\:\\ 0\\.10737222841218004\ \(0\)\
\-\ chest\\:\\ 0\\.10553765824488337\ \(0\)\
\-\ reduce\\:\\ 0\\.10179131223429001\ \(0\)\
\-\ size\\:\\ 0\\.10153372203788687\ \(0\)\
\-\ lobular\\:\\ 0\\.10147553710266227\ \(0\)\
\-\ may\\:\\ 0\\.10061534456531628\ \(0\)\
\-\ well\\:\\ 0\\.0968111946997644\ \(0\)\
\-\ are\\:\\ 0\\.09483444714347185\ \(0\)\
\-\ possibly\\:\\ 0\\.0939573695287676\ \(0\)\
\-\ solitary\\:\\ 0\\.09149032409457421\ \(0\)\
\-\ the\\:\\ 0\\.08976368307759824\ \(0\)\
\-\ embolization\\:\\ 0\\.08712540940602377\ \(0\)\
\-\ left\\:\\ 0\\.08525421765234063\ \(0\)\
\-\ is\\:\\ 0\\.082131764210277\ \(0\)\
\-\ be\\:\\ 0\\.08110704577485381\ \(0\)\
\-\ with\\:\\ 0\\.07830090559809756\ \(0\)\
\-\ vessels\\:\\ 0\\.07757628115270117\ \(0\)\
\-\ malformation\\:\\ 0\\.07710260243502119\ \(0\)\
\-\ emobolization\\:\\ 0\\.07638338937683244\ \(0\)\
\-\ intended\\:\\ 0\\.07190726818688281\ \(0\)\
\-\ mm\\:\\ 0\\.07154294162135984\ \(0\)\
\-\ treatment\\:\\ 0\\.0714309781614288\ \(0\)\
\-\ venous\\:\\ 0\\.07137361619148577\ \(0\)\
\-\ armstrong\\:\\ 0\\.07030967138323484\ \(0\)\
\-\ connections\\:\\ 0\\.06895892253212392\ \(0\)\
\-\ opted\\:\\ 0\\.06583355019328521\ \(0\)\
\-\ emanating\\:\\ 0\\.06583355019328521\ \(0\)\
\-\ on\\:\\ 0\\.060384851020627926\ \(0\)\
\-\ from\\:\\ 0\\.059555314005388264\ \(0\)\
\-\ include\\:\\ 0\\.05948078582998311\ \(0\)\
\-\ offered\\:\\ 0\\.05933230727231639\ \(0\)\
\-\ events\\:\\ 0\\.05892467457330457\ \(0\)\
\-\ discuss\\:\\ 0\\.05853516498898296\ \(0\)\
\-\ enhancement\\:\\ 0\\.0575405525471792\ \(0\)\
\-\ forming\\:\\ 0\\.057460859342745606\ \(0\)\
\-\ cm\\:\\ 0\\.057413466815078\ \(0\)\
\-\ ct\\:\\ 0\\.05708884066071191\ \(0\)\
\-\ endovascular\\:\\ 0\\.05537177730709463\ \(0\)\
\-\ hypoxia\\:\\ 0\\.05511019003597863\ \(0\)\
\-\ symptoms\\:\\ 0\\.05469750353575896\ \(0\)\
\-\ prompt\\:\\ 0\\.05436925399301186\ \(0\)\
\-\ embolic\\:\\ 0\\.05390796207653567\ \(0\)\
\-\ interventional\\:\\ 0\\.0532585892787188\ \(0\)\
\-\ edition\\:\\ 0\\.05305240275798139\ \(0\)\
\-\ was\\:\\ 0\\.052260403240414116\ \(0\)\
\-\ or\\:\\ 0\\.052166276178880575\ \(0\)\
\-\ mosby\\:\\ 0\\.051907840427607876\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.05173081374352806\ \(0\)\
\-\ autosomal\\:\\ 0\\.0515572927697687\ \(0\)\
\-\ malformations\\:\\ 0\\.05043028006038088\ \(0\)\
\-\ eventually\\:\\ 0\\.049845895368830793\ \(0\)\
\-\ criteria\\:\\ 0\\.049567696675054396\ \(0\)\
\-\ but\\:\\ 0\\.049434943898997545\ \(0\)\
\-\ measured\\:\\ 0\\.04929805931349703\ \(0\)\
\-\ of\\:\\ 0\\.04890884297678668\ \(0\)\
\-\ contrast\\:\\ 0\\.04857301113037795\ \(0\)\
\-\ noncontrast\\:\\ 0\\.04829553599941427\ \(0\)\
\-\ systems\\:\\ 0\\.04829553599941427\ \(0\)\
\-\ determined\\:\\ 0\\.04761239621249243\ \(0\)\
\-\ also\\:\\ 0\\.04702266402313388\ \(0\)\
\-\ dominant\\:\\ 0\\.046777238586109375\ \(0\)\
\-\ thickness\\:\\ 0\\.04638772900178777\ \(0\)\
\-\ angiography\\:\\ 0\\.0461992803875713\ \(0\)\
\-\ lobulated\\:\\ 0\\.04610655441298221\ \(0\)\
\-\ overall\\:\\ 0\\.045923995250872165\ \(0\)\
\-\ diseases\\:\\ 0\\.045923995250872165\ \(0\)\
\-\ 3rd\\:\\ 0\\.04565709574993046\ \(0\)\
\-\ discovered\\:\\ 0\\.045569905748672264\ \(0\)\
\-\ intravenous\\:\\ 0\\.045569905748672264\ \(0\)\
\-\ somewhat\\:\\ 0\\.045483574776171105\ \(0\)\
\-\ nature\\:\\ 0\\.04413282592506019\ \(0\)\
\-\ medicine\\:\\ 0\\.04405949894628249\ \(0\)\
\-\ direct\\:\\ 0\\.04405949894628249\ \(0\)\
\-\ visible\\:\\ 0\\.04405949894628249\ \(0\)\
\-\ dyspnea\\:\\ 0\\.043986780497164354\ \(0\)\
\-\ phase\\:\\ 0\\.04277156414787823\ \(0\)\
\-\ subsequently\\:\\ 0\\.04264638312136137\ \(0\)\
\-\ important\\:\\ 0\\.042341037842560506\ \(0\)\
\-\ disorder\\:\\ 0\\.04228122516780035\ \(0\)\
\-\ apparent\\:\\ 0\\.04181687691267123\ \(0\)\
\-\ frequently\\:\\ 0\\.041163467016036515\ \(0\)\
\-\ total\\:\\ 0\\.040956060343124316\ \(0\)\
\-\ characteristic\\:\\ 0\\.040409777238229555\ \(0\)\
\-\ diameter\\:\\ 0\\.04017229595983842\ \(0\)\
\-\ radiology\\:\\ 0\\.04003283641938462\ \(0\)\
\-\ references\\:\\ 0\\.03985027725727457\ \(0\)\
\-\ recommended\\:\\ 0\\.039760404440412685\ \(0\)\
\-\ nodules\\:\\ 0\\.03971581135267449\ \(0\)\
\-\ al\\:\\ 0\\.03971581135267449\ \(0\)\
\-\ many\\:\\ 0\\.039409856782573506\ \(0\)\
\-\ appear\\:\\ 0\\.03936700817479909\ \(0\)\
\-\ et\\:\\ 0\\.03915585282896165\ \(0\)\
\-\ single\\:\\ 0\\.03843523961573665\ \(0\)\
\-\ similar\\:\\ 0\\.038096002818935056\ \(0\)\
\-\ enhanced\\:\\ 0\\.03805910793146259\ \(0\)\
\-\ related\\:\\ 0\\.03798578095268491\ \(0\)\
\-\ cough\\:\\ 0\\.037318171888495816\ \(0\)\
\-\ radiographic\\:\\ 0\\.03708449076462573\ \(0\)\
\-\ referred\\:\\ 0\\.03698621845053404\ \(0\)\
\-\ http\\:\\ 0\\.03695370441386263\ \(0\)\
\-\ they\\:\\ 0\\.03571493820924072\ \(0\)\
\-\ risk\\:\\ 0\\.03571493820924072\ \(0\)\
\-\ typically\\:\\ 0\\.035089749022438915\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.034028570753681715\ \(0\)\
\-\ extending\\:\\ 0\\.0338902122555322\ \(0\)\
\-\ right\\:\\ 0\\.0331439383673867\ \(0\)\
\-\ vascular\\:\\ 0\\.03299907712507096\ \(0\)\
\-\ finding\\:\\ 0\\.032855594013188376\ \(0\)\
\-\ often\\:\\ 0\\.03261496041577594\ \(0\)\
\-\ patient\\:\\ 0\\.03251497421805883\ \(0\)\
\-\ between\\:\\ 0\\.032477583223913\ \(0\)\
\-\ usually\\:\\ 0\\.03146716929891511\ \(0\)\
\-\ enhancing\\:\\ 0\\.03131238076861688\ \(0\)\
\-\ for\\:\\ 0\\.030299908494625098\ \(0\)\
\-\ syndrome\\:\\ 0\\.030133789180605157\ \(0\)\
\-\ abnormal\\:\\ 0\\.030030089475303025\ \(0\)\
\-\ months\\:\\ 0\\.029095091921536576\ \(0\)\
\-\ these\\:\\ 0\\.028226306150917653\ \(0\)\
\-\ follow\\:\\ 0\\.02694604986795624\ \(0\)\
\-\ associated\\:\\ 0\\.026345642273054\ \(0\)\
\-\ imaging\\:\\ 0\\.02626860860919175\ \(0\)\
\-\ can\\:\\ 0\\.02623034425655605\ \(0\)\
\-\ most\\:\\ 0\\.026013509066327503\ \(0\)\
\-\ present\\:\\ 0\\.025648731199642102\ \(0\)\
\-\ in\\:\\ 0\\.024869101745810203\ \(0\)\
\-\ up\\:\\ 0\\.024725507275902406\ \(0\)\
\-\ findings\\:\\ 0\\.02466941411699362\ \(0\)\
\-\ multiple\\:\\ 0\\.02444856476775344\ \(0\)\
\-\ surgical\\:\\ 0\\.024294155083639968\ \(0\)\
\-\ lesion\\:\\ 0\\.023963738041894757\ \(0\)\
\-\ seen\\:\\ 0\\.02353235366778071\ \(0\)\
\-\ as\\:\\ 0\\.02008059521909863\ \(0\)\
